Organogenesis Holdings Inc.

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

ORGO$0.94+3.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY

(amounts in thousands, except share amounts)

Additional
Redeemable Convertible Preferred Stock · Common Stock · Paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	Capital	Deficit	Stockholders’ Equity
Balance as of December 31, 2024	130,000	$122,419	125,730,236	$13	$302,994	$(40,110)	$262,897
Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock	—	2,748	—	—	(2,748)	—	(2,748)
Exercise of stock options	—	—	20,016	—	25	—	25
Vesting of RSUs, net of shares surrendered to pay taxes	—	—	1,103,284	—	(1,796)	—	(1,796)
Stock-based compensation expense	—	—	—	—	3,367	—	3,367
Net loss	—	—	—	—	—	(18,843)	(18,843)
Balance as of March 31, 2025	130,000	$125,167	126,853,536	$13	$301,842	$(58,953)	$242,902
Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock	—	2,810	—	—	(2,810)	—	(2,810)
Stock-based compensation expense	—	—	—	—	2,542	—	2,542
Net loss	—	—	—	—	—	(9,392)	(9,392)
Balance as of June 30, 2025	130,000	$127,977	126,853,536	$13	$301,574	$(68,345)	$233,242
Accretion to redemption value and cumulative dividends on redeemable convertible preferred stock	—	2,874	—	—	(2,874)	—	(2,874)
Exercise of stock options	—	—	57,184	—	130	—	130
Vesting of RSUs, net of shares surrendered to pay taxes	—	—	722	—	(2)	—	(2)
Stock-based compensation expense	—	—	—	—	3,065	—	3,065
Net income	—	—	—	—	—	21,567	21,567
Balance as of September 30, 2025	130,000	$130,851	126,911,442	$13	$301,893	$(46,778)	$255,128

CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (Continued)

(amounts in thousands, except share amounts)

Additional
Redeemable Convertible Preferred Stock · Common Stock · Paid-in · Accumulated · Total
	Shares	Amount	Shares	Amount	Capital	Deficit	Stockholders’ Equity
Balance as of December 31, 2023	—	$—	131,316,396	$13	$319,621	$(40,971)	$278,663
Exercise of stock options	—	—	152,250	—	180	—	180
Vesting of RSUs, net of shares surrendered to pay taxes	—	—	1,070,694	—	(1,120)	—	(1,120)
Stock-based compensation expense	—	—	—	—	2,407	—	2,407
Net loss	—	—	—	—	—	(2,100)	(2,100)
Balance as of March 31, 2024	—	$—	132,539,340	$13	$321,088	$(43,071)	$278,030
Vesting of RSUs, net of shares surrendered to pay taxes	—	—	34,898	—	(54)	—	(54)
Stock-based compensation expense	—	—	—	—	2,568	—	2,568
Net loss	—	—	—	—	—	(17,043)	(17,043)
Balance as of June 30, 2024	—	$—	132,574,238	$13	$323,602	$(60,114)	$263,501
Exercise of stock options	—	—	1,500	—	4	—	4
Vesting of RSUs, net of shares surrendered to pay taxes	—	—	764	—	(1)	—	(1)
Stock-based compensation expense	—	—	—	—	2,712	—	2,712
Net income	—	—	—	—	—	12,331	12,331
Balance as of September 30, 2024	—	$—	132,576,502	$13	$326,317	$(47,783)	$278,547

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.